Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.
Lisata Therapeutics M&A Deal with Marea Therapeutics, Inc.
Lisata Therapeutics filed an amendment to its previous 8-K to provide required audited financial statements and pro forma financial information following its completed acquisition of Marea Therapeutics, Inc. The filing includes combined financial statements for Marea and M2 Therapeutics for the years 2024 and 2025, as well as interim 2026 data.
Lisata Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders approved several key proposals. Most notably, stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 44.76 million shares and the 2026 Employee Stock Purchase Plan with an initial reserve of 3.73 million shares.
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors as a Class III member and a member of the Audit Committee, effective October 13, 2026. The appointment expands the company's board from seven to eight members. Mr. Farrow is a veteran biopharmaceutical executive currently serving as CFO and Chief Strategy Officer of Tarsus Pharmaceuticals.